Colorectal cancer test is FDA moment of sorts

Share this article:

Exact Sciences hit a two-fer with Monday's approval of its colorectal cancer test: Cologuard was the first approved fecal-based screening test for the disease, and it was also the first product the FDA and the Centers for Medicare and Medicaid Services approved on the very same day through the Parallel Review program.

Regulatory Focus explains that the idea for the Parallel Review program started in 2011 and that it has had some setbacks, such as in January, when the two government agencies were set to approve Medtronic's Symplicity Renal Denervation Device, but it failed to hit its Phase-III clinical trial goals and could not be greenlighted.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters